
Supernus Pharmaceuticals (SUPN) Stock Forecast & Price Target
Supernus Pharmaceuticals (SUPN) Analyst Ratings
Bulls say
Supernus Pharmaceuticals Inc. holds significant market opportunities with products like Qelbree for ADHD, which is poised for growth due to its unique non-stimulant characteristics and strong clinical data, with projected sales exceeding $600 million. The company also benefits from a two-year patent extension for Qelbree until 2035, providing additional protection and potential for sustained revenue. Furthermore, Supernus’s robust balance sheet enables it to pursue acquisitions valued between $500 million to $1.5 billion, allowing for strategic expansion within its market.
Bears say
Supernus Pharmaceuticals is facing a negative outlook due to disappointing Phase 2b data from its SPN-820 trial for treatment-resistant depression, prompting a downgrade from an optimistic position. The company's market potential could be diluted by challenges in commercial execution, compounded by inherent clinical trial risks that may hinder regulatory approvals for new or expanded indications. Additionally, clinicians' reluctance to alter prescribing practices based on their experiences with existing therapies further threatens the adoption of Supernus's products, potentially impacting sales and growth.
This aggregate rating is based on analysts' research of Supernus Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Supernus Pharmaceuticals (SUPN) Analyst Forecast & Price Prediction
Start investing in Supernus Pharmaceuticals (SUPN)
Order type
Buy in
Order amount
Est. shares
0 shares